Hypertension, Malignant

NEW YORK and BAAR, Switzerland, Aug. 1, 2023 /PRNewswire/ -- Vyera Pharmaceuticals, LLC ("Vyera") and Phoenixus AG ("Phoenixus") today announced that they have entered into an Asset Purchase Agreement related to Daraprim and Vecamyl. The aggregate consideration to be paid for the sale and transfer of the purchased assets and the assignment of the certain contracts, subject to adjustment, shall be $650,000 together with the assumption of post-closing liabilities. The closing of the transaction is subject to satisfaction of certain conditions, including without limitation approval of the United States Bankruptcy Court for the District of Delaware with which Vyera and Phoenixus, together with affiliated parties, have filed voluntary petitions for relief under Chapter 11 of Title 11 of the United States Code and have elected to proceed under Subchapter V thereunder. The bankruptcy cases are jointly administered under Case No. 23-10605 (JKS). As part of the Subchapter V proceedings, Vyera filed a motion seeking authorization of its proposed bidding procedures under which to conduct its 363 sale. Additional information about this process and the proposed asset sale, as well as other documents relating to Vyera's Subchapter V proceedings, is available through Vyera's claims and noticing agent's website: . DLA Piper LLP is serving as the Vyera's legal counsel. SierraConstellation Partners LLC is serving as Chief Restructuring Officer and financial advisor, and Alvarez and Marsal Securities LLC is serving as investment banker. For more information about the sale process, interested parties should contact Alvarez and Marsal Securities LLC. About Daraprim DARAPRIM is a prescription medication that contains pyrimethamine for the treatment of toxoplasmosis when used with a sulfonamide (e.g., sulfadoxine). Toxoplasmosis is a serious, sometimes fatal infection caused by the Toxoplasma gondii (T. gondii) parasite, one of the most common parasites in the world. About Vecamyl VECAMYL® (mecamylamine HCI) is indicated for the management of moderately severe to severe essential hypertension and in uncomplicated cases of malignant hypertension. About Vyera Vyera is a United States based biopharmaceutical company committed to developing and commercializing treatments that address serious and rare diseases with high unmet medical needs. Vyera supports programs that offer financial assistance to patients in need and gives discounts to organizations that provide care to underserved populations. Vyera's research and development efforts focus on novel treatment options for toxoplasmosis and other rare or serious health conditions. . About Phoenixus AG Phoenixus AG is a Swiss based global biopharmaceutical enterprise using a virtual pharma and centralized services development model to reduce the risk, costs and timing of product development across its portfolio companies. Forward-Looking Statements This press release contains certain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995, that involve risks, uncertainties, and assumptions that are difficult to predict. Buyer and Vyera and Phoenixus (collectively, the "Companies") intend that such forward-looking statements be subject to the safe harbors created thereby. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as "believes," "hopes," "intends," "estimates," "expects," "projects," "plans," "anticipates" and variations thereof, or the use of future tense, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. The Companies' forward-looking statements are not guarantees of performance, and actual results could vary materially from those contained in or expressed by such statements due to risks and uncertainties including: (i) the sufficiency of the Companies' cash position, (ii) the Companies' ability to raise additional capital to fund its operations, (iii) the Companies' ability to meet its debt obligations, if any, (iv) the Companies' ability to enter into partnership or licensing arrangements with third parties, (v) the Companies' ability to identify patients to enroll in its clinical trials in a timely fashion, (vi) the Companies' ability to achieve approval of a marketable product, (vii) the design, implementation and conduct of the Companies' clinical trials, (viii) the results of the Companies' clinical trials, including the possibility of unfavorable clinical trial results, (ix) the market for, and marketability of, any product that is approved, (x) the existence or development of vaccines, drugs, or other treatments that are viewed by medical professionals or patients as superior to the Companies' products, (xi) regulatory initiatives, compliance with governmental regulations and the regulatory approval process, (xii) general economic and business conditions, (xiii) changes in foreign, political, and social conditions, and (xiv) various other matters, many of which are beyond the Companies' control. Except as required by law, neither Company undertakes any responsibility to update any forward-looking statements to take into account events or circumstances that occur after the date of this press release. Media Contact [email protected] SOURCE Vyera Pharmaceuticals

January 8, 2015 By Mark Terry , BioSpace.com Breaking News Staff Martin Shkreli , founder and former chief executive officer of Retrophin Inc. , is being investigated by U.S. prosecutors for possible securities violations, claimed Bloomberg News Thursday. Shkreli is also, according to the same source, under investigation by the U.S. Securities and Exchange Commission ( SEC ) for similar reasons related to distribution of stock without letting shareholders know. In September 2014 Shkreli was replaced by Retrophin’s board over poor management skills and some bad PR due to his unprofessional use of Twitter. He also sold about $4.5 million in company stock at an average price of $15 per share without informing shareholders. Shkreli has also been accused by Citizens for Responsibility and Ethics in 2012 of spreading “unfounded and inaccurate rumors about drugs owned by companies he was shorting.” The group requested an investigation by U.S. Attorney Preet Bharara in Manhattan. Retrophin currently has three products, Thiola, for the prevention of kidney stone formation, Chenodal, for the treatment of gall stones, and Vecamyl, for the treatment of moderately severe to severe essential hypertension and uncomplicated cases of malignant hypertension. It also has several products in various preclinical and Phase I, II and III trials. In an August analysis , Adam Feuerstein wrote, “All the drugs bought or licensed by Retrophin are under-utilized and under-priced, which the company believes can be reversed by repurposing them to treat rare diseases at much higher prices. To grow Retrophin quickly, Shkreli is borrowing from the commercial roll-up and pricing strategies employed successfully — some would say controversially — by specialty pharmaceutical companies Valeant Pharmaceuticals and Questcor Pharmaceuticals .” Prior to being chief executive of Retrophin , Shkreli was chief investment officer of MSMB Capital Management , which focuses on healthcare investments. Since October 2014 he had been chief executive officer of Turing Pharmaceuticals , a private drug company focused on orphan, psychiatry and infectious diseases. On Twitter yesterday Shkreli claimed the reports were “misleading and confused on an old situation that is no longer relevant.” Spokespeople for the SEC, Retrophin and for U.S. Attorney Loretta Lynch in Brooklyn have declined to comment. In another tweet from Jan. 7, Shkreli wrote, “bberg ( Bloomberg ) is rehashing my 2012 ‘call for investigation’. Why I am so interesting to the media I will never understand.” “Martin impressed me with his ambition and his knowledge of drug development, which is why I am invested in the company,” said an anonymous Retrophin shareholder in an August article . “But then you see him selling [Retrophin] stock, missing deadlines and now this unprofessional Twitter stuff and it gets frustrating. You start to question if he’s mature enough to run the company.”